Sun Pharma today announced that one of its wholly-owned subsidiaries plans to launch a first-in-class oral drug, Bempedoic Acid, in India for reducing Low-Density Lipoprotein (LDL) cholesterol. The company will launch the drug under the brand name “Brillo.”
Brillo is a first-in-class drug which has a new mechanism of action compared to the currently available lipid-lowering agents. It is indicated for people who have an inherited genetic disorder that causes high cholesterol levels or established heart disease where cholesterol levels remain high, despite lifestyle changes and the use of maximum tolerated dose of statins, the company said in a statement.
One in four deaths in India is now because of heart diseases, with ischemic heart disease and stroke responsible for >80 per cent of this burden. The burden of heart disease at 272 per 1,00,000 population in India is higher than the global average of 235 per 1,00,000 population, the statement added.